Picano E. Dipyridamole-echocardiography test: the historical background and the physiologic basis. Eur Heart J. 1989;10(4):365–376. https://doi.org/10.1093/oxfordjournals.eurheartj.a059494..
DOI: 10.1093/oxfordjournals.eurheartj.a059494
Smith J.B., Mills D.C. Inhibition of adenosine 3′5′-cyclic monophosphate phosphodiesterase. Biochem J. 1970;120(4):20P. https://doi.org/10.1042/bj1200020pa..
DOI: 10.1042/bj1200020pa
Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978;311(8077):1286–1289. https://doi.org/10.1016/s0140-6736(78)91269-2..
DOI: 10.1016/s0140-6736(78)91269-2
Newsholme E.A. The control of the mechanism and the hormonal control of adenosine. Essays Biochem. 1978;14:82–123. Available at: https://pubmed.ncbi.nlm.nih.gov/365523.https://pubmed.ncbi.nlm.nih.gov/365523
Newsholme E.A. The control of the mechanism and the hormonal control of adenosine. Essays Biochem. 1978;14:82–123. Available at: https://pubmed.ncbi.nlm.nih.gov/365523.https://pubmed.ncbi.nlm.nih.gov/365523
Dresse A., Chevolet C., Delapierre D., Masset H., Weisenberger H., Bozler G., Heinzel G. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol. 1982;23(3):229–234. https://doi.org/10.1007/BF00547559..
DOI: 10.1007/BF00547559
German D.C., Kredich N.M., Bjornsson T.D. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther. 1989;45(1):80–84. https://doi.org/10.1038/clpt.1989.12..
DOI: 10.1038/clpt.1989.12
Born G.V., Cross M.J. Effect of adenosine diphosphate on the concentration of platelets in circulating blood. Nature. 1963;197:974–976. https://doi.org/10.1038/197974a0..
DOI: 10.1038/197974a0
Mills D.C., Smith J.B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets. Biochem J. 1971;121(2):185–196. https://doi.org/10.1042/bj1210185..
DOI: 10.1042/bj1210185
Gresele P., Arnout J., Deckmyn H., Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986;55:12–18. https://pubmed.ncbi.nlm.nih.gov/3704998.https://pubmed.ncbi.nlm.nih.gov/3704998
Gresele P., Arnout J., Deckmyn H., Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986;55:12–18. https://pubmed.ncbi.nlm.nih.gov/3704998.https://pubmed.ncbi.nlm.nih.gov/3704998
Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983;50:852–856. https://pubmed.ncbi.nlm.nih.gov/6665766.https://pubmed.ncbi.nlm.nih.gov/6665766
Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983;50:852–856. https://pubmed.ncbi.nlm.nih.gov/6665766.https://pubmed.ncbi.nlm.nih.gov/6665766
Nakamura T., Uchiyama S., Yamazaki M., Iwata M. Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovasc Dis. 2002;14(3-4):234–238. https://doi.org/10.1159/000065669..
DOI: 10.1159/000065669
Heistad D.D., Marcus M.L., Gourley J.K., Busija D.W. Effect of adenosine and dipyridamole on cerebral blood flow. Am J Physiol. 1981;240(5):H775-780. https://doi.org/10.1152/ajpheart.1981.240.5.H775..
DOI: 10.1152/ajpheart.1981.240.5.H775
Суслина З.А., Танашян М.М. Антитромботическая терапия в ангионеврологии. М.; 2004.
Танашян М.М., Домашенко М.А. Применение Курантила при хронических цереброваскулярных заболеваниях. Атмосфера. Нервные болезни. 2005;(3):8–11. Режим доступа: https://www.neurology.ru/sites/default/files/assets/documents/2016/02/3-2005-8.pdf?download=1.https://www.neurology.ru/sites/default/files/assets/documents/2016/02/3-2005-8.pdf?download=1
Танашян М.М., Домашенко М.А. Применение Курантила при хронических цереброваскулярных заболеваниях. Атмосфера. Нервные болезни. 2005;(3):8–11. Режим доступа: https://www.neurology.ru/sites/default/files/assets/documents/2016/02/3-2005-8.pdf?download=1.https://www.neurology.ru/sites/default/files/assets/documents/2016/02/3-2005-8.pdf?download=1
Iuliano L., Pedersen J.Z., Rotilio G., Ferro D., Violi F. A potent chainbreaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med. 1995;18(2):239–247. https://doi.org/10.1016/0891-5849(94)e0123-z..
DOI: 10.1016/0891-5849(94)e0123-z
Iuliano L., Colavita A.R., Camastra C., Bello V., Quintarelli C., Alessandroni M. et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119(7):1438–1446. https://doi.org/10.1111/j.1476-5381.1996.tb16056.x..
DOI: 10.1111/j.1476-5381.1996.tb16056.x
Kusmic C., Picano E., Busceti C.L., Petersen C., Barsacchi R. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res. 2000;47(3):510–514. https://doi.org/10.1016/s0008-6363(00)00058-4..
DOI: 10.1016/s0008-6363(00)00058-4
Chakrabarti S., Vitseva O., Iyu D., Varghese S., Freedman J.E. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther. 2005;315(2):494–500. https://doi.org/10.1124/jpet.105.089987..
DOI: 10.1124/jpet.105.089987
Liao J.K., Bettmann M.A., Sandor T., Tucker J.I., Coleman S.M., Creager M.A. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68(4):1027–1034. https://doi.org/10.1161/01.res.68.4.1027..
DOI: 10.1161/01.res.68.4.1027
Radomski M.W., Rees D.D., Dutra A., Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol. 1992;107(3):745–749. https://doi.org/10.1111/j.1476-5381.1992.tb14517.x..
DOI: 10.1111/j.1476-5381.1992.tb14517.x
Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83(5):1774–1777. https://doi.org/10.1172/JCI114081..
DOI: 10.1172/JCI114081
Kurose I., Kubes P., Wolf R., Anderson D.C., Paulson J., Miyasaka M., Granger D.N. Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ Res. 1993;73(1):164–171. https://doi.org/10.1161/01.res.73.1.164..
DOI: 10.1161/01.res.73.1.164
De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96(1):60–68. https://doi.org/10.1172/JCI118074..
DOI: 10.1172/JCI118074
Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377(6546):239–242. https://doi.org/10.1038/377239a0..
DOI: 10.1038/377239a0
Steudel W., Ichinose F., Huang P.L., Hurford W.E., Jones R.C., Bevan J.A. et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997;81(1):34–41. https://doi.org/10.1161/01.res.81.1.34..
DOI: 10.1161/01.res.81.1.34
Moroi M., Zhang L., Yasuda T., Virmani R., Gold H.K., Fishman M.C., Huang P.L. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101(6):1225–1232. https://doi.org/10.1172/JCI1293..
DOI: 10.1172/JCI1293
Huang Z., Huang P.L., Ma J., Meng W., Ayata C., Fishman M.C., Moskowitz M.A. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996;16(5):981–987. https://doi.org/10.1097/00004647-199609000-00023..
DOI: 10.1097/00004647-199609000-00023
Aktas B., Utz A., Hoenig-Liedl P., Walter U., Geiger J. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003;34(3):764–769. https://doi.org/10.1161/01.STR.0000056527.34434.59..
DOI: 10.1161/01.STR.0000056527.34434.59
Kawasaki K., Smith R.S. Jr., Hsieh C.M., Sun J., Chao J., Liao J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol. 2003;23(16):5726–5737. https://doi.org/10.1128/MCB.23.16.5726-5737.2003..
DOI: 10.1128/MCB.23.16.5726-5737.2003
Akhtar M., Ordovas K., Martin A., Higgins C.B., Michaels A.D. Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest Heart Fail. 2007;13(3):130–135. https://doi.org/10.1111/j.1527-5299.2007.06047.x..
DOI: 10.1111/j.1527-5299.2007.06047.x
Jagathesan R., Rosen S.D., Foale R.A., Camici P.G., Picano E. Effects of longterm oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: a substudy of the persantinein stable angina (PISA) study. J Cardiovasc Pharmacol. 2006;48(3):110–116. https://doi.org/10.1097/01.fjc.0000245404.20922.9f..
DOI: 10.1097/01.fjc.0000245404.20922.9f
Gamboa A., Abraham R., Diedrich A., Shibao C., Paranjape S.Y., Farley G., Biaggioni I. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke. 2005;36(10):2170–2175. https://doi.org/10.1161/01.STR.0000179044.37760.9d..
DOI: 10.1161/01.STR.0000179044.37760.9d
Ye Y., Lin Y., Perez-Polo R., Huang M.H., Hughes M.G., McAdoo D. J. et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007;293(1):H813-H818. https://doi.org/10.1152/ajpheart.00210.2007..
DOI: 10.1152/ajpheart.00210.2007
Weyrich A.S., Denis M.M., Kuhlmann-Eyre J.R., Spencer E.D., Dixon D.A., Marathe G.K. et al. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111(5):633–642. https://doi.org/10.1161/01.CIR.0000154607.90506.45..
DOI: 10.1161/01.CIR.0000154607.90506.45
Brozna J.P., Horan M., Carson S.D. Dipyridamole inhibits O2- release and expression of tissue factor activity by peripheral blood monocytes stimulated with lipopolysaccharide. Thromb Res. 1990;60(2):141–156. https://doi.org/10.1016/0049-3848(90)90293-l..
DOI: 10.1016/0049-3848(90)90293-l
Coeugniet E., Bendtzen K., Bendixen G. Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin. Acta Med Scand. 1976;199(1–2):99–104. https://doi.org/10.1111/j.0954-6820.1976.tb06698.x..
DOI: 10.1111/j.0954-6820.1976.tb06698.x
Dong H., Osmanova V., Epstein P.M., Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem Biophys Res Commun. 2006;345(2):713–719. https://doi.org/10.1016/j.bbrc.2006.04.143..
DOI: 10.1016/j.bbrc.2006.04.143
Al-Bahrani A., Taha S., Shaath H., Bakhiet M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res. 2007;4(1):31–37. https://doi.org/10.2174/156720207779940716..
DOI: 10.2174/156720207779940716
Elsherbiny N.M., Al-Gayyar M.M., Abd El Galil K.H. Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. Life Sci. 2015;143:8–17. https://doi.org/10.1016/j.lfs.2015.10.026..
DOI: 10.1016/j.lfs.2015.10.026
Melani A., Cipriani S., Corti F., Pedata F. Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. Ann N Y Acad Sci. 2010;1207:89–96. https://doi.org/10.1111/j.1749-6632.2010.05732.x..
DOI: 10.1111/j.1749-6632.2010.05732.x
Kim H.H., Liao J.K. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008;28(3):s39-42. https://doi.org/10.1161/ATVBAHA.107.160226..
DOI: 10.1161/ATVBAHA.107.160226
Galabov A.S., Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother. 1984;38(8):412–413. Available at: https://pubmed.ncbi.nlm.nih.gov/6084526.https://pubmed.ncbi.nlm.nih.gov/6084526
Galabov A.S., Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother. 1984;38(8):412–413. Available at: https://pubmed.ncbi.nlm.nih.gov/6084526.https://pubmed.ncbi.nlm.nih.gov/6084526
Insel P.A., Murray F., Yokoyama U., Romano S., Yun H., Brown L. et al. cAMP and Epac in the regulation of tissue fi brosis. Br J Pharmacol. 2012;166(2):447–456. https://doi.org/10.1111/j.1476-5381.2012.01847.x..
DOI: 10.1111/j.1476-5381.2012.01847.x
Sanada S., Asanuma H., Koretsune Y., Watanabe K., Nanto S., Awata N. et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Hypertens Res. 2007;30(10):913–919. https://doi.org/10.1291/hypres.30.913..
DOI: 10.1291/hypres.30.913
Kuo K., Hung S., Tseng W., Liu J.S., Lin M.H., Hsu C.C., Tarng D.C. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. Oncotarget. 2017;9(4):5368–5377. https://doi.org/10.18632/oncotarget.19850..
DOI: 10.18632/oncotarget.19850
Lee G., Choong H., Chiang G., Woo K. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology. 1997;3(1):117–121. https://doi.org/10.1111/j.1440-1797.1997.tb00201.x..
DOI: 10.1111/j.1440-1797.1997.tb00201.x
Tonew E., Indulen M.K., Dzeguze D.R. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol. 1982;26(3):125–129. https://pubmed.ncbi.nlm.nih.gov/6127012.https://pubmed.ncbi.nlm.nih.gov/6127012
Tonew E., Indulen M.K., Dzeguze D.R. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol. 1982;26(3):125–129. https://pubmed.ncbi.nlm.nih.gov/6127012.https://pubmed.ncbi.nlm.nih.gov/6127012
Kuzmov K., Galabov A.S., Radeva K., Kozhukharova M., Milanov K. Epidemiological trial of the prophylactic eff ectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1985;(6):26–30. Available at: https://pubmed.ncbi.nlm.nih.gov/3898670.https://pubmed.ncbi.nlm.nih.gov/3898670
Kuzmov K., Galabov A.S., Radeva K., Kozhukharova M., Milanov K. Epidemiological trial of the prophylactic eff ectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1985;(6):26–30. Available at: https://pubmed.ncbi.nlm.nih.gov/3898670.https://pubmed.ncbi.nlm.nih.gov/3898670
Tenser R.B., Gaydos A., Hay K.A. Inhibition of herpes simplex virus reactivation by dipyridamole. Antimicrob Agents Chemother. 2001;45(12):3657–3659. https://doi.org/10.1128/AAC.45.12.3657-3659.2001..
DOI: 10.1128/AAC.45.12.3657-3659.2001
Szebeni J., Wahl S.M., Popovic M., Wahl L.M., Gartner S., Fine R.L. et al. Dipyridamole potentiates the inhibition by 3’-azido-3’-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci USA. 1989;86(10):3842–3846. https://doi.org/10.1073/pnas.86.10.3842..
DOI: 10.1073/pnas.86.10.3842
Macatangay B., Jackson E., Abebe K., Comer D., Cyktor J., Klamar-Blain C. et al. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. J Infect Dis. 2020;221(10):1598–1606. https://doi.org/10.1093/infdis/jiz344..
DOI: 10.1093/infdis/jiz344
Kozhukharova M.S., Slepushkin A.N., Radeva Kh.T., Lavrukhina L.A., Demidova S.A. Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases. Vopr Virusol. 1987;32(3):294–297. https://pubmed.ncbi.nlm.nih.gov/3314143.https://pubmed.ncbi.nlm.nih.gov/3314143
Kozhukharova M.S., Slepushkin A.N., Radeva Kh.T., Lavrukhina L.A., Demidova S.A. Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases. Vopr Virusol. 1987;32(3):294–297. https://pubmed.ncbi.nlm.nih.gov/3314143.https://pubmed.ncbi.nlm.nih.gov/3314143
Lette J., Tatus J., Fraser S., Miller D., Waters D., Heller G. et al. Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. Journal of Nuclear Cardiology. 1995;2(1):3–17. https://doi.org/10.1016/s1071-3581(05)80003-0..
DOI: 10.1016/s1071-3581(05)80003-0
Balakumar P., Nyo Y.H., Renushia R., Raaginey D., Oh A.N., Varatharajan R., Dhanaraj S.A. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res. 2014;87:144–150. https://doi.org/10.1016/j.phrs.2014.05.008..
DOI: 10.1016/j.phrs.2014.05.008
Guo S., Stins M., Ning M., Lo E.H. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis. 2010;30(3):290–296. https://doi.org/10.1159/000319072..
DOI: 10.1159/000319072
Парфенов В.А., Вербицкая С.В. Антитромбоцитарная терапия во вторичной профилактике ишемического инсульта. Медицинский совет. 2015;(5):6–13. Режим доступа: https://www.med-sovet.pro/jour/article/view/165.https://www.med-sovet.pro/jour/article/view/165
Парфенов В.А., Вербицкая С.В. Антитромбоцитарная терапия во вторичной профилактике ишемического инсульта. Медицинский совет. 2015;(5):6–13. Режим доступа: https://www.med-sovet.pro/jour/article/view/165.https://www.med-sovet.pro/jour/article/view/165
Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1–13. https://doi.org/10.1016/s0022-510x(96)00308-5..
DOI: 10.1016/s0022-510x(96)00308-5
Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665–1673. https://doi.org/10.1016/S0140-6736(06)68734-5..
DOI: 10.1016/S0140-6736(06)68734-5
Танашян М.М., Домашенко М.А. Дипиридамол в комплексной терапии хронических цереброваскулярных заболеваний. Нервные болезни. 2012;(3):27–30. Режим доступа: https://www.atmosphere-ph.ru/modules/Magazines/articles/nervo/an_3_2012_27.pdf.https://www.atmosphere-ph.ru/modules/Magazines/articles/nervo/an_3_2012_27.pdf
Танашян М.М., Домашенко М.А. Дипиридамол в комплексной терапии хронических цереброваскулярных заболеваний. Нервные болезни. 2012;(3):27–30. Режим доступа: https://www.atmosphere-ph.ru/modules/Magazines/articles/nervo/an_3_2012_27.pdf.https://www.atmosphere-ph.ru/modules/Magazines/articles/nervo/an_3_2012_27.pdf
Боголепова А.Н. Лечение когнитивных нарушений сосудистого генеза. Эффективная фармакотерапия. 2015;(23):14–19. Режим доступа: https://www.elibrary.ru/item.asp?id=23860546.https://www.elibrary.ru/item.asp?id=23860546
Боголепова А.Н. Лечение когнитивных нарушений сосудистого генеза. Эффективная фармакотерапия. 2015;(23):14–19. Режим доступа: https://www.elibrary.ru/item.asp?id=23860546.https://www.elibrary.ru/item.asp?id=23860546
Liu X., Li Z., Liu S., Sun J., Chen Z., Jiang M. et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020;10(7):1205–1215. https://doi.org/10.1016/j.apsb.2020.04.008..
DOI: 10.1016/j.apsb.2020.04.008